Shin Poong

Product category
  • 3-day cure, artemisinin-based combination therapy (pyronaridine-artesunate)

Therapeutic indication
  • Treatment of uncomplicated malaria caused by P. falciparum or by P. vivax in adults and children ≥20 kg

  • Once daily for 3 days

  • 28-day PCR-corrected ACPR* >98%

  • 42-day PCR-corrected ACPR* 90%–95%

Key features
  • Only artemisinin-based combination therapy approved by a stringent regulatory authority for both P. falciparum;P. vivax (blood-stage)
  • No food restrictions
  • 2-year shelf life
  • Country order fulfilment by major procurement bodies

  • Positive opinion from EMA (Article 58). Cross-listed on WHO list of prequalified medicines. Included in WHO Essential Medicines List. WHO Guidelines for Malaria now consider pyronaridine-artesunate to be ''a safe and efficacious treatment for uncomplicated malaria.''
  • Approved in 28 countries
  • Included in 10 national treatment guidelines
Next milestone
  • Formal inclusion in WHO Malaria Treatment Guidelines
  • Continued commercial introduction in malaria endemic countries
  • Approval of 30-month shelf life
  • Development project team led by University of Iowa

MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response